← Eichor
Condition: Hormone Receptor Positive Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hormone Receptor Positive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemothera
NA · 1 location(s) · Gencurix, Inc. · NCT04278469Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Phase 1 · 8 location(s) · Orano Med Theranostics, SAS · NCT05283330First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Parti
Phase 1/Phase 2 · 65 location(s) · Eli Lilly and Company · NCT05768139S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic
NA · 723 location(s) · SWOG Cancer Research Network · NCT03723928BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 · 63 location(s) · BeOne Medicines · NCT06120283Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
Phase 1/Phase 2 · 2 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04923542Tirzepatide Weight Loss for MRD+ Early Breast Cancer
Phase 2 · 1 location(s) · Baylor Research Institute · NCT06517212CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT07366112Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Recepto
NA · 3 location(s) · University of Miami · NCT06123988VS-6766+Abema+Fulv in Met HR+/HER- BC
Phase 1/Phase 2 · 3 location(s) · Adrienne G. Waks · NCT05608252Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stag
Phase 2 · 17 location(s) · Merck Sharp & Dohme LLC · NCT06797635A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Adva
Phase 2 · 1 location(s) · Shanghai Henlius Biotech · NCT06832202Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended En
Phase N/A · 12 location(s) · Shengjing Hospital · NCT04476485Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Phase 1/Phase 2 · 17 location(s) · Aminex Therapeutics, Inc. · NCT07287917Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
Phase N/A · 1 location(s) · Mayo Clinic · NCT06388122A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Recept
Phase 2 · 1 location(s) · University of Washington · NCT07112053Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT07546695Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
Phase 2 · 1 location(s) · Seoul National University Hospital · NCT05536128A Study of Revaree Plus in People With Breast Cancer
Phase 4 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07042581Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormon
Phase N/A · 24 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06805812A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Le
Phase 3 · 232 location(s) · Hoffmann-La Roche · NCT06790693Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
Phase 2 · 11 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT04965766Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NA · 1 location(s) · Brigham and Women's Hospital · NCT04030507Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Nagoya City University · NCT07164976Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NA · 39 location(s) · Natera, Inc. · NCT07214532Prognostic and Predictive Role of Intrinsic Molecular Subtypes in BRCA-associated Breast Cancer
Phase N/A · 6 location(s) · Angela Toss · NCT07617025A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Phase 1 · 18 location(s) · Totus Medicines · NCT05683418A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R
Phase 2 · 49 location(s) · Hoffmann-La Roche · NCT07405801Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treat
Phase 2 · 5 location(s) · Delcath Systems Inc. · NCT06875128
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.